Change in (18)F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment

BACKGROUND: Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether (18)F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant g...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Shigeru, Hirata, Kenji, Toyonaga, Takuya, Kobayashi, Kentaro, Ishi, Yukitomo, Motegi, Hiroaki, Kobayashi, Hiroyuki, Shiga, Tohru, Tamaki, Nagara, Terasaka, Shunsuke, Houkin, Kiyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148016/
https://www.ncbi.nlm.nih.gov/pubmed/27936194
http://dx.doi.org/10.1371/journal.pone.0167917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148016/
https://www.ncbi.nlm.nih.gov/pubmed/27936194
http://dx.doi.org/10.1371/journal.pone.0167917

Ejemplares similares